Literature DB >> 6876691

Antithrombin III deficiency in ischaemic stroke.

V Hossmann, W D Heiss, H Bewermeyer.   

Abstract

AT III activity and concentration were measured in 36 patients (mean age 65.5 yrs, range 43-77 yrs) with ischaemic stroke within maximally 48 h of the acute event. In 12 patients (= 33%) AT III activity was reduced below 18.4 IU/ml: 50% of these patients showed normal and 50% reduced AT III concentration of less than 22 mg/dl. In 15 patients AT III activity and concentration were measured in the acute phase on admission to hospital and 12 months later. In the acute phase, AT III activity was reduced when compared with AT III concentration (y = 0.19 chi + 15.5) and did not correlate with the latter. 12 months later, however, AT III activity and concentration correlated significantly (r = 0.92; p less than 0.001) and the regression line was steeper (y = 0.8 chi). During the acute phase of ischaemic stroke, intravascular coagulation is evidently increased and inactive AT III-thrombin complexes are formed, whereby the concentration of active AT III decreases. A patient with progressive stroke and reduced AT III activity of 14.2 IU/ml was therefore substituted with AT III concentrate. The further neurological course was favourable.

Entities:  

Mesh:

Year:  1983        PMID: 6876691     DOI: 10.1007/bf01487340

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  15 in total

1.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

2.  Plasma antithrombin III and factor VIII antigen in relation to angiographic findings, angina and blood groups in middle-aged men.

Authors:  H Stormorken; J Erikssen
Journal:  Thromb Haemost       Date:  1977-12-15       Impact factor: 5.249

3.  The effect of total hip replacement and general surgery on antithrombin III in relation to venous thrombosis.

Authors:  S N Gitel; E A Salvati; S Wessler; H J Robinson; M H Worth
Journal:  J Bone Joint Surg Am       Date:  1979-07       Impact factor: 5.284

4.  Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement.

Authors:  S Sagar; D Nairn; J D Stamatakis; F H Maffei; A F Higgins; D P Thomas; V V Kakkar
Journal:  Lancet       Date:  1976-05-29       Impact factor: 79.321

5.  Familial thrombosis: inherited deficiency of antithrombin III.

Authors:  M Mackie; B Bennett; D Ogston; A S Douglas
Journal:  Br Med J       Date:  1978-01-21

6.  Heparin cofactor activity and antithrombin III concentration in plasma related to age and sex.

Authors:  O R Odegärd; M K Fagerhol; M Lie
Journal:  Scand J Haematol       Date:  1976-10

7.  [Antithrombin III: reference values found with a chromogenic substrate (chromozym TH) (author's transl)].

Authors:  R Hesse; W Tritschler; G Castelfranchi; W Bablok
Journal:  Blut       Date:  1981-04

8.  Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease.

Authors:  T B Wahlberg; M Blombäck; I Overmark
Journal:  Acta Med Scand       Date:  1980

9.  Immunochemical analysis of active and inactive antithrombin III.

Authors:  E J McKay
Journal:  Br J Haematol       Date:  1980-10       Impact factor: 6.998

10.  [Antithrombin III deficiency and tendency to thrombosis (author's transl)].

Authors:  K Lechner; E Thaler; H Niessner; C Nowotny; H Partsch
Journal:  Wien Klin Wochenschr       Date:  1977-04-01       Impact factor: 1.704

View more
  1 in total

Review 1.  A synopsis of the clinical uses of argatroban.

Authors:  M Moledina; M Chakir; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.